At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 617 enrolled
Drug / intervention
Herpes Zoster (HZ) Vaccine +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)
In Brief
A Phase 2 clinical trial evaluating Herpes Zoster (HZ) Vaccine and Placebo for Rheumatoid Arthritis and 7 related conditions. Completed, enrolled 617 participants across 34 sites.
Detailed Summary
The VaricElla zosteR VaccinE (VERVE) trial evaluates the safety and effectiveness of the Herpes zoster (HZ) vaccine for shingles, Zostavax, in patients over 50 years old with arthritis and other diseases who are using anti-tumor necrosis factor (TNF) therapy and who have not previously received the vaccine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis, Inflammatory Arthritis, Arthritis, Psoriatic Arthritis, Psoriasis, Ankylosing Spondylitis, Enteropathic Arthritis, Crohn's Disease
CountriesUnited States
CollaboratorsOregon Health and Science University
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 2015
Enrollment StartMay 2016
Primary CompletionDec 2019
Study CompletionDec 2020
TodayJul 2026
First PostedSep 2, 2015
Enrollment StartMay 1, 2016
Primary CompletionDec 1, 2019
Study CompletionDec 1, 2020
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 10.8 years ago
Interventions
Herpes Zoster (HZ) Vaccinebiological
Placebodrug